SOUTH SAN FRANCISCO, Calif.,
Sept. 2, 2020 /PRNewswire/
-- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that
Raul Rodriguez, the company's
president and chief executive officer, is scheduled to participate
in a panel discussion on COVID-19 during Citi's
15th Annual BioPharma Virtual Conference
taking place September 9-10,
2020.
Citi Panel Details:
Panel Topic: State of Play for COVID-19 Therapeutics
Date: Wednesday, September 9
Time: 9:50 a.m. Eastern Time
To access the event live or the archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium
hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK)
inhibitor, for the treatment of adult patients with chronic immune
thrombocytopenia who have had an insufficient response to a
previous treatment. The product has been approved by the European
Commission for the treatment of chronic immune thrombocytopenia in
adult patients who are refractory to other treatments and is
marketed in Europe under the name
TAVLESSE® (fostamatinib). Fostamatinib is
currently being studied in an investigator-sponsored trial
conducted by Imperial College London for the treatment of COVID-19
pneumonia1.
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a
completed Phase 1 study of
R8351, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) inhibitor
program; and an ongoing Phase 1 study of
R5521, a proprietary molecule
from its receptor-interacting protein kinase (RIP) inhibitor
program. In addition, Rigel has product candidates in clinical
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use
or indication is investigational and has not been proven safe or
effective by any regulatory authority.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-participate-in-citis-15th-annual-biopharma-virtual-conference-301122559.html
SOURCE Rigel Pharmaceuticals, Inc.